Big pharma continues to move in the direction of biotech investments and clinical research in cancer research...here with Wyeth, Roche and Genentech working together...BD
Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced the initiation of the INTORACT (INvestigation of TORISEL and Avastin Combination Therapy) study, a worldwide randomized, open-label, phase 3b study comparing TORISEL(R) (temsirolimus) plus Avastin(R) (bevacizumab) versus Avastin plus interferon-alfa for first-line treatment of patients with advanced renal cell carcinoma (RCC). Wyeth Research is conducting the INTORACT study with the support and assistance of Roche and Genentech.
Wyeth Initiates INTORACT -- A New Clinical Trial To Examine TORISEL Plus Avastin For First-Line Treatment Of Advanced Kidney Cancer
0 comments :
Post a Comment